

Inherited Bleeding Disorders in Pediatric Patients: From Diagnosis to Management (Recording)

Stanford University School of Medicine

References

1. Abshire, T., Cox-Gill, J., Kempton, C. L., Leebeek, F. W., Carcao, M., Kouides, P., Donfield, S., & Berntorp, E. (2015). Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. *Journal of thrombosis and haemostasis : JTH*, 13(9), 1585–1589. <https://doi.org/10.1111/jth.12995>
2. Callaghan, M. U., Negrier, C., Paz-Priel, I., Chang, T., Chebon, S., Lehle, M., Mahlangu, J., Young, G., Kruse-Jarres, R., Mancuso, M. E., Niggli, M., Howard, M., Bienz, N. S., Shima, M., Jiménez-Yuste, V., Schmitt, C., Asikanius, E., Levy, G. G., Pipe, S. W., & Oldenburg, J. (2021). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. *Blood*, 137(16), 2231–2242. <https://doi.org/10.1182/blood.2020009217>
3. Castaman, G., Di Minno, G., De Cristofaro, R., & Peyvandi, F. (2022). The Arrival of Gene Therapy for Patients with Hemophilia A. *International journal of molecular sciences*, 23(18), 10228. <https://doi.org/10.3390/ijms231810228>
4. Cornell University. (n.d.). Primary hemostasis. *Cornell University College of Veterinary Medicine, ECLINPATH*. <https://eclinpath.com/hemostasis/physiology/primary-hemostasis/>
5. Croteau, S. E., Wang, M., & Wheeler, A. P. (2021). 2021 clinical trials update: Innovations in hemophilia therapy. *American journal of hematology*, 96(1), 128–144. <https://doi.org/10.1002/ajh.26018>
6. Hemophilia, von Willebrand Disease & Platelet Disorders Handbook, The. (n.d.) Nosebleeds. *The Hemophilia, von Willebrand Disease & Platelet Disorders Handbook*. <https://www.hog.org/handbook/article/3/33/nosebleeds>
7. Lavin, M., Aguila, S., Schneppenheim, S., Dalton, N., Jones, K. L., O'Sullivan, J. M., O'Connell, N. M., Ryan, K., White, B., Byrne, M., Rafferty, M., Doyle, M. M., Nolan, M., Preston, R. J. S., Budde, U., James, P., Di Paola, J., & O'Donnell, J. S. (2017). Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. *Blood*, 130(21), 2344–2353. <https://doi.org/10.1182/blood-2017-05-786699>
8. Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., ... Evatt, B. L. (2007). Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. *The New England journal of medicine*, 357(6), 535–544. <https://doi.org/10.1056/NEJMoa067659>
9. National Bleeding Disorders Foundation. (n.d.). Shared Decision-making. *National Bleeding Disorders Foundation*. <https://www.bleeding.org/bleeding-disorders-a-z/treatment/shared-decision-making>
10. Oldenburg J. (2015). Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. *Blood*, 125(13), 2038–2044. <https://doi.org/10.1182/blood-2015-01-528414>

11. Ozelo, M. C., & Yamaguti-Hayakawa, G. G. (2022). Impact of novel hemophilia therapies around the world. *Research and practice in thrombosis and haemostasis*, 6(3), e12695. <https://doi.org/10.1002/rth2.12695>
12. Pynnonen, M. (2016). 10 ways to stop a bloody nose. *University of Michigan, Michigan Medicine*. <https://www.michiganmedicine.org/health-lab/10-ways-stop-bloody-nose>
13. Relke, N., Chornenki, N. L. J., & Sholzberg, M. (2021). Tranexamic acid evidence and controversies: An illustrated review. *Research and practice in thrombosis and haemostasis*, 5(5), e12546. <https://doi.org/10.1002/rth2.12546>
14. Sidonio, R. F., Jr, Boban, A., Dubey, L., Inati, A., Kiss, C., Boda, Z., Lissitchkov, T., Nemes, L., Novik, D., Peteva, E., Taher, A. T., Timofeeva, M. A., Vilchevska, K. V., Vdovin, V., Werner, S., Knaub, S., & Djambas Khayat, C. (2024). von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease. *Blood advances*, 8(6), 1405–1414. <https://doi.org/10.1182/bloodadvances.2023011742>
15. Skinner, M. W., Nugent, D., Wilton, P., O'Mahony, B., Dolan, G., O'Hara, J., & Berntorp, E. (2020). Achieving the unimaginable: Health equity in haemophilia. *Haemophilia : the official journal of the World Federation of Hemophilia*, 26(1), 17–24. <https://doi.org/10.1111/hae.13862>
16. Srivastava, A., Santagostino, E., Dougall, A., Kitchen, S., Sutherland, M., Pipe, S. W., Carcao, M., Mahlangu, J., Ragni, M. V., Windyga, J., Llinás, A., Goddard, N. J., Mohan, R., Poonnoose, P. M., Feldman, B. M., Lewis, S. Z., van den Berg, H. M., Pierce, G. F., & WFH Guidelines for the Management of Hemophilia panelists and co-authors (2020). WFH Guidelines for the Management of Hemophilia, 3rd edition. *Haemophilia : the official journal of the World Federation of Hemophilia*, 26 Suppl 6, 1–158. <https://doi.org/10.1111/hae.14046>
17. Thornburg, C. D., & Coffin, D. (2024). How clinicians and persons with hemophilia may approach shared decision-making. *Expert review of hematology*, 17(6), 193–196. <https://doi.org/10.1080/17474086.2024.2353761>
18. Warren, B. B., Thornhill, D., Stein, J., Fadell, M., Ingram, J. D., Funk, S., Norton, K. L., Lane, H. D., Bennett, C. M., Dunn, A., Recht, M., Shapiro, A., & Manco-Johnson, M. J. (2020). Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. *Blood advances*, 4(11), 2451–2459. <https://doi.org/10.1182/bloodadvances.2019001311>
19. World Federation of Hemophilia. (n.d.). Treatment and care. *World Federation of Hemophilia*. <https://wfh.org/treatment-and-care/#sdm-tool>